Partnerships

Orbis Medicines strikes a partnership with Novo, Dualitas Therapeutics enters collaboration with Roche, and Aethlon Medical has agreed to merge with North Immunology.

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.

Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.

Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science.

CAR-T safety halts, a rare disease trial failure, a China licensing deal, an mRNA flu vaccine advance, and nine new MFN agreements.

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 billion, including a $75 million upfront payment.

FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Israel Ortiz makes the case for preventive maintenance in manufacturing.

DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi.

Osivax and GC Biopharma agree to co-develop an influenza vaccine combining Osivax's OVX836 with GC Biopharma's GC FLU.

From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million biosimilar collaboration — this week's deals and approvals reveal a lot about how pharmaceutical strategy is evolving.

Amplitude Therapeutics enters a collaboration with Eli Lilly to develop trans-amplifying RNA vaccines, while Chai Discovery partners with Bristol Myers Squibb to deploy its AI molecular folding and design models across BMS's antibody discovery portfolio.

UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's subsidiary has licensed European commercialization rights to Tenpoint's Yuvezzi.

Henlius Biotech has granted Sandoz exclusive ex-China commercialization rights to up to 10 monoclonal antibody and ADC biosimilars for up to $322 million.

From a $1.32 billion rare epilepsy acquisition to AI drug discovery partnerships, biotech IPOs, and a rare disease investment rebound — here's what moved the market this week.

Christopher Savage, managing director, Propensity4, and chief of staff, Inizio Engage, on creating lasting impact over chasing the next opportunity.

Mereo BioPharma licenses its lung disease treatment alvelestat to Sentynl Therapeutics, Krieger Scientific's Joseph Morwald examines what's driving a surge in FDA warning letters, and IQVIA's Christopher Wooden and Tom Woods make the case for persona-based HCP engagement.

BeOne Medicines and Revolution Medicines enter a two-part deal pairing BeOne's PRMT5 inhibitor and EGFR×MET trispecific antibody with Revolution's four clinical RAS(ON) inhibitors.

The AstraZeneca–BMS merger story explained: what was reported, what was denied, what regulators would scrutinize, and what it means for pharma.

In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva executive discusses how agentic AI is surfacing HCP insights that traditional field reporting has historically missed.

Jazz Pharmaceuticals agrees to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones for ABS-1230.

Novo Nordisk selects AWS as its preferred AI partner for drug discovery, Innate Pharma partners with Sobi, and Innovent Biologics secures exclusive commercialization rights for Vanflyta in China.

Johnson & Johnson moves to acquire Sail Biomedicines, Processa acquires Vidya Therapeutics, and Relation partners with GSK on AI-driven target discovery collaboration.

Nuvation Bio’s president, CEO, and founder discusses the company’s mission, approach to developing a global strategy, and how it manages its increasing pipeline.

Bristol Myers Squibb is deploying Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems to build what it claims is the most powerful AI computing infrastructure in life sciences.

Insilico Medicine and Bora Pharmaceuticals entered a strategic alliance to pair Insilico's AI drug discovery platform with Bora's development and manufacturing infrastructure.